TY - JOUR
T1 - Estroprogestin vs. gonadotrophin agonists plus estroprogestin in the treatment of endometriosis-related pelvic pain
T2 - A randomized trial
AU - Parazzini, Fabio
AU - Di Cintio, Elisabetta
AU - Chatenoud, Liliane
AU - Moroni, Simona
AU - Ardovino, Italo
AU - Struzziero, Elisario
AU - Falsetti, Leopoldo
AU - Bianchi, Albino
AU - Bracco, Gianluca
AU - Pellegrini, Alessandra
AU - Bertulessi, Carlo
AU - Romanini, Carlo
AU - Zupi, Errico
AU - Massobrio, Marco
AU - Guidetti, Daniela
AU - Troiano, Luigi
AU - Beretta, Paolo
AU - Franchi, Massimo
PY - 2000/1
Y1 - 2000/1
N2 - Objective: This is a randomized clinical trial comparing estroprogestin (E/P) pill given for 12 months vs. gonadotrophin releasing hormone agonist (GNRHa) given for 4 months followed by E/P pill treatment for 8 months in the relief of endometriosis-related pelvic pain. Methods: Eligible for the study were women with laparoscopically confirmed endometriosis and pelvic pain lasting 3-12 months after diagnosis. Eligible women were randomly assigned to treatment with E/P pill (gestroden 0.75 mg and ethynlestradiol 0.03 mg) for 12 months (47 patients) vs. tryptorelin 3.75 mg slow release every 28 days for 4 months followed by E/P pill for 8 months (55 patients). Results: At baseline, dysmenorrhea was reported in 46 women allocated to E/P pill only (97.9%), and in all the 55 women allocated to GNRHa+E/P pill. The corresponding value at the 12 months follow-up visit was 14 subjects (35.9%) and 16 subjects (34.8%). The baseline median values of the multidimensional and analog scale were for dysmenorrhea 4 and 6 in the EP only and 3 and 6 in the GNRHa+E/P group. The corresponding value at the 12 months follow-up visit were 2 and 6 and 0 and 5. Non-menstrual pain was reported, respectively, at baseline and 12 month visit by 46 (97.9%) and 15 (38.5%) subjects in the E/P pill group and 49 (89.1%) and 17 (37.0%) of the GNRHa+E/P pill one. The baseline median values of the multidimensional and analog scale were for non-menstrual pain 3 and 5 in the E/P only and 2 and 6 in the GNRHa+E/P group. The corresponding values at the 12 month follow-up visit were 0 and 4 and 0 and 4. These differences between the two groups were not statistically significant. Conclusions: 1 year after randomization, the two treatment schedules show similar relief of pelvic pain in women with endometriosis. Copyright (C) 2000 Elsevier Science Ireland Ltd.
AB - Objective: This is a randomized clinical trial comparing estroprogestin (E/P) pill given for 12 months vs. gonadotrophin releasing hormone agonist (GNRHa) given for 4 months followed by E/P pill treatment for 8 months in the relief of endometriosis-related pelvic pain. Methods: Eligible for the study were women with laparoscopically confirmed endometriosis and pelvic pain lasting 3-12 months after diagnosis. Eligible women were randomly assigned to treatment with E/P pill (gestroden 0.75 mg and ethynlestradiol 0.03 mg) for 12 months (47 patients) vs. tryptorelin 3.75 mg slow release every 28 days for 4 months followed by E/P pill for 8 months (55 patients). Results: At baseline, dysmenorrhea was reported in 46 women allocated to E/P pill only (97.9%), and in all the 55 women allocated to GNRHa+E/P pill. The corresponding value at the 12 months follow-up visit was 14 subjects (35.9%) and 16 subjects (34.8%). The baseline median values of the multidimensional and analog scale were for dysmenorrhea 4 and 6 in the EP only and 3 and 6 in the GNRHa+E/P group. The corresponding value at the 12 months follow-up visit were 2 and 6 and 0 and 5. Non-menstrual pain was reported, respectively, at baseline and 12 month visit by 46 (97.9%) and 15 (38.5%) subjects in the E/P pill group and 49 (89.1%) and 17 (37.0%) of the GNRHa+E/P pill one. The baseline median values of the multidimensional and analog scale were for non-menstrual pain 3 and 5 in the E/P only and 2 and 6 in the GNRHa+E/P group. The corresponding values at the 12 month follow-up visit were 0 and 4 and 0 and 4. These differences between the two groups were not statistically significant. Conclusions: 1 year after randomization, the two treatment schedules show similar relief of pelvic pain in women with endometriosis. Copyright (C) 2000 Elsevier Science Ireland Ltd.
KW - Endometriosis
KW - Estroprogestins
KW - Gonadotrophin agonists
KW - Pelvic pain
KW - Randomized trial
UR - http://www.scopus.com/inward/record.url?scp=0033987260&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033987260&partnerID=8YFLogxK
U2 - 10.1016/S0301-2115(99)00131-1
DO - 10.1016/S0301-2115(99)00131-1
M3 - Article
C2 - 10659911
AN - SCOPUS:0033987260
VL - 88
SP - 11
EP - 14
JO - European Journal of Obstetrics, Gynecology and Reproductive Biology
JF - European Journal of Obstetrics, Gynecology and Reproductive Biology
SN - 0028-2243
IS - 1
ER -